Andolast acts at different cellular levels to inhibit immunoglobulin E synthesis

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 1, 2009, Pages 85-94

  Malerba, M ^a   Mennuni, L ^b   Piepoli, T ^b   Caselli, G ^b   Makovec, F ^b   Rovati, L C ^b   D'Amato, M ^b   Ferrari, Flora ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Rotta Research Laboratorium   (Italy)

Author keywords

Andolast (CR 2039); Asthma; CD40 antigen; Immunoglobuli E (IgE); Immunoglobulin class switching; Interleukin 4

Indexed keywords

ANDOLAST; ANTIASTHMATIC AGENT; BECLOMETASONE; CD3 ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; INTERLEUKIN 4; MESSENGER RNA; MONOCLONAL ANTIBODY CD28; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; B LYMPHOCYTE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME IMMUNOASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE ACTIVATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

EID: 62649151478     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200110     Document Type: Article

References (31)

1. Makovec F, Peris W, Revel L, Giovanetti R, Redaelli D, Rovati LC. Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives. J Med Chem 1992; 35:3633-40.
2. Revel L, Colombo S, Ferrari F, Folco G, Rovati LC, Makovec F. CR 2039, a new bis-(1H-tetrazol-5-y1)phenylbenzamide derivative with potential for the topical treatment of asthma. Eur J Pharmacol 1992; 229:45-53.
3. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2003; 25:387-408.
4. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2007; 29:359-73.
5. Persiani S, D'Amato M, Makovec F, Arshad SH, Holgate ST, Rovati LC. Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. Biopharm Drug Dispos 2001; 22:73-81.
6. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2007. Available from: http://www.ginasthma.org. Accessed July, 2008.
7. Alam R, Gorska M. 3. Lymphocytes. J Allergy Clin Immunot 2003; 111:S476-85.
8. Romagnani S, Del Prete G. How T cells direct IgE switching. In IgE regulation: molecular mechanisms. D. Vercelli, ed. John Wiley and Sons Chichester, 1997; p. 2-3.
9. Prussin C, Metcalfe DD. 5. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2006; 117: S450-6.
10. Chaplin DD. 1. Overview of the immune response. J Allergy Clin Immunol 2003; 111:S442-59.
11. Loh RK, Jabara HH, Geha RS. Mechanisms of inhibition of IgE synthesis by nedocromil sodium: nedocromil sodium inhibits deletional switch recombination in human B cells. J Allergy Clin Immunol 1996; 97:1141-50.
12. Jabara HH, Brodeur SR, Geha RS. Glucocorticoids upregulate CD40 ligand expression and induce CD40L-dependent immunoglobulin isotype switching. J Clin Invest 2001; 107:371-8.
13. Toda M, Sakaguchi Y, Morimoto K. Correlation between serum IgE and salivary cortisol levels in subjects with type I allergic disorders. Int J Immunopathol Pharmacol 2007; 20:203-5.
14. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA 2000; 284:3043-5.
15. Jabara HH, Fu SM, Geha RS, Vercelli D. CD40 and IgE: Synergism between anti-CD40 niAb and IL-4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med 1990; 172:1861-4.
16. Cosmi L, Annunziato F, Iwasaki M, Galli G, Manetti R, Maggi E, Nagata K, Romagnani S. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 cytotoxic cells in the health and disease. Eur J Immunol 2000; 30:2972-9.
17. Thienes CP, De ML, Monticelli S, Busslinger M, Gould HJ, Vercelli D. The transcription factor B cell-specific activator protein (BSAP) enhances both IL-4- and CD40-mediated activation of the human epsilon germline promoter. J Immunol 1997; 158: 5874-82.
18. Vercelli D, De ML, Monticelli S, Di BC, Agresti A. To E or not to E? Can an IL-4-induced B cell choose between IgE and IgG4? Int Arch Allergy Immunol 1998; 116:1-4.
19. Loh RK, Jabara HH, Geha RS. Disodium cromoglycate inhibits S mu-->S epsilon deletional switch recombination and IgE synthesis in human B cells. J Exp Med 1994; 180:663-71.
20. Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, Francis JN. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007; 120:688-95.
21. Belvisi MG, Hele DJ, Birrell MA. New anti-inflammatory therapies and targets for asthma and chronic obstructive pulmonary disease. Expert Opin Ther Targets 2004; 8:265-85.
22. Fahy JV. Anti-IgE: lessons learned from effects on airway inflammation and asthma exacerbation. J Allergy Clin Immunol 2006; 117:1230-2.
23. Borish LC, Steinke JW. 2. Cytokines and chemokines. J Allergy Clin Immunol 2003; 111:S460-75.
24. Poulsen LK, Hummelshoj L. Triggers of IgE class switching and allergy development. Ann Med 2007; 39:440-56.
25. Kajiwara K, Shinazawa M, Morishima H, Yanagihara Y. Differential effect of IL-4 and IL-13 on the expression of recombination-activating genes in mature B cells from human peripheral blood. Cell Immunol 2004; 227:121-8.
26. Frotscher B, Anton K, Worm M. Inhibition of IgE production by the imidazoquinoline resiquimod in non-allergic and allergic donors. J Invest Dermatol 2002; 119:1059-64.
27. Kimura I, Tanizaki Y, Goda Y, Komagoe H, Kitani H. Decrease in reactivity of basophils by immunotherapy with housedust extract. Clin Allergy 1985; 15:1-7.
28. Wachholz PA, Durham SR. Induction of 'blocking' IgG antibodies during immunotherapy. Clin Exp Allergy 2003; 33:1171-4.
29. Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172:3252-9.
30. Rossi RE, Monasterolo G. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol 2005; 18:277-85.
31. Fiset PO, Cameron L, Hamid Q. Local isotype switching to IgE in airway mucosa. J Allergy Clin Immunol 2005; 116:233-6.